Delving into the Latest Updates on Temoporfin with Synapse

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

2,3-dihydro-5,10,15,20-tetra(m-hydroxyphenyl)porphyrin, Foscan, Temoporfin (USAN/INN)

+ [8]

Target

Reactive oxygen species

Mechanism

Reactive oxygen species stimulants, Photosensitizers

Therapeutic Areas

Neoplasms

Active Indication

Squamous Cell Carcinoma of Head and Neck

Inactive Indication

Advanced Head and Neck CarcinomaCarcinoma bile duct non-resectable

Originator Organization

biolitec AG

Active Organization

biolitec Pharma Ltd.

Inactive Organization-

Drug Highest PhaseApproved

First Approval Date

EU (24 Oct 2001),

Squamous Cell Carcinoma of Head and Neck

RegulationOrphan Drug (US)

Login to view timeline

Structure

Molecular FormulaC44H32N4O4

InChIKeyLYPFDBRUNKHDGX-SOGSVHMOSA-N

CAS Registry122341-38-2

This phase I trial studies the side effects and best dose of photodynamic therapy during surgery in treating patients with non-small cell lung cancer that can be removed by surgery. Photodynamic therapy uses a drug, such as temoporfin, that becomes active when it is exposed to a certain kind of light. When the drug is active, cancer cells are killed. This may be a better way to treat patients with non-small cell lung cancer.

Start Date21 Feb 2014

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

NCT01718223 / WithdrawnNot ApplicableIIT

A Pilot Study of Interstitial Photodynamic Therapy for Recurrent Squamous Cell Carcinoma of the Oropharynx and Oral Cavity

This pilot clinical trial studies photodynamic therapy using temoporfin before surgery in treating patients with recurrent oral cavity or oropharyngeal cancer. Photodynamic therapy uses a drug, such as temoporfin, that is absorbed by tumor cells. The drug becomes active when it is exposed to light. When the drug is active, tumor cells are killed. Giving photodynamic therapy using temoporfin before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be removed.

Start Date01 Dec 2013

Sponsor / Collaborator

Roswell Park Comprehensive Cancer Center

[+2]

100 Clinical Results associated with Temoporfin

Login to view more data

100 Translational Medicine associated with Temoporfin

Login to view more data

100 Patents (Medical) associated with Temoporfin

Login to view more data

525

Literatures (Medical) associated with Temoporfin

01 Dec 2024·Computational Biology and Chemistry

Drug repositioning identifies potential autophagy inhibitors for the LIR motif p62/SQSTM1 protein

Article

Author: Cordani, Marco ; Moosavi, Mohammad Amin ; Nayeri, Zahra ; Saei, Ali Kian ; Asghari, Narjes

Autophagy is a critical cellular process for degrading damaged organelles and proteins under stressful conditions and has casually been shown to contribute to tumor survival and drug resistance. Sequestosome-1 (SQSTM1/p62) is an autophagy receptor that interacts with its binding partners via the LC3-interacting region (LIR). The p62 protein has been a highly researched target for its critical role in selective autophagy. In this study, we aimed to identify FDA-approved drugs that bind to the LIR motif of p62 and inhibit its LIR function, which could be useful targets for modulating autophagy. To this, the homology model of the p62 protein was predicted using biological data, and docking analysis was performed using Molegro Virtual Docker and PyRx softwares. We further assessed the toxicity profile of the drugs using the ProTox-II server and performed dynamics simulations on the effective candidate drugs identified. The results revealed that the kanamycin, velpatasvir, verteporfin, and temoporfin significantly decreased the binding of LIR to the p62 protein. Finally, we experimentally confirmed that Kanamycin can inhibit autophagy-associated acidic vesicular formation in breast cancer MCF-7 and MDA-MB 231 cells. These repositioned drugs may represent novel autophagy modulators in clinical management, warranting further investigation.

01 Nov 2024·International Journal of Biological Macromolecules

Octadecylamine modified gelatin-based biodegradable packaging film with good water repellency and improved moisture service reliability

Article

Author: Gao, Jianjin ; Li, Jinchao ; Zhang, Yaping ; Chen, Liang ; Zhang, Xinai ; Qiang, Taotao

Industrial gelatin is a good candidate for fabricating biodegradable packaging film, but the strong hydrophilicity of gelatin-based film lowers its moisture service reliability. Herein, we demonstrated a low surface energy water repellency surface design combined with covalent cross-linking for decreasing the water absorption and improving the moisture service reliability. Biodegradable octadecylamine (ODA) was chosen as the low surface energy providing material to fabricate the water repellency surface through a dehydration condensation reaction between the amine groups of ODA and gelatin chains via tetra-hydroxymethyl phosphonium chloride (THPC) in an aqueous phase. THPC also was employed as the cross-linking agent to form covalent bonding between the gelatin chains. The results determined that ODA modification and covalent cross-linking endowed the gelatin-based film with good water repellency and improved moisture service reliability. But high dose of ODA would result in phase separation and mechanical strength loss of the fabricated film. Additionally, ODA modification did not change the biodegradability of gelatin-based film, all the modified films were completely biodegradable in natural soil. Considering the sustainable modification process and abundant raw materials, the proposed strategy facilitates the effective utilization of low value industrial gelatin and provides a facile way for gelatin-based film as biodegradable packaging film.

09 Sep 2024·Biomacromolecules

Temoporfin-Conjugated PEGylated Poly(N,N-dimethylacrylamide)-Coated Upconversion Colloid for NIR-Induced Photodynamic Therapy of Pancreatic Cancer

Article

Author: Vasylyshyn, Taras ; Horák, Daniel ; Větvička, David ; Shapoval, Oleksandr ; Poučková, Pavla ; Engstová, Hana ; Kabešová, Martina ; Oleksa, Viktoriia ; Patsula, Vitalii

Photodynamic therapy (PDT) has the potential to cure pancreatic cancer with minimal side effects. Visible wavelengths are primarily used to activate hydrophobic photosensitizers, but in clinical practice, these wavelengths do not sufficiently penetrate deeper localized tumor cells. In this work, NaYF₄:Yb³⁺,Er³⁺,Fe²⁺ upconversion nanoparticles (UCNPs) were coated with polymer and labeled with meta-tetra(hydroxyphenyl)chlorin (mTHPC; temoporfin) to enable near-infrared light (NIR)-triggered PDT of pancreatic cancer. The coating consisted of alendronate-terminated poly[N,N-dimethylacrylamide-co-2-aminoethylacrylamide]-graft-poly(ethylene glycol) [P(DMA-AEM)-PEG-Ale] to ensure the chemical and colloidal stability of the particles in aqueous physiological fluids, thereby also improving the therapeutic efficacy. The designed particles were well tolerated by the human pancreatic adenocarcinoma cell lines CAPAN-2, PANC-1, and PA-TU-8902. After intratumoral injection of mTHPC-conjugated polymer-coated UCNPs and subsequent exposure to 980 nm NIR light, excellent PDT efficacy was achieved in tumor-bearing mice.

100 Deals associated with Temoporfin

Login to view more data

External Link

KEGG	Wiki	ATC	Drug Bank
D06066	Temoporfin	L01XD05	DB11630

R&D Status

Approved

10 top approved records.

Login

to view more data

Indication	Country/Location	Organization	Date
Squamous Cell Carcinoma of Head and Neck	LI	biolitec Pharma Ltd.	24 Oct 2001
Squamous Cell Carcinoma of Head and Neck	IS	biolitec Pharma Ltd.	24 Oct 2001
Squamous Cell Carcinoma of Head and Neck	NO	biolitec Pharma Ltd.	24 Oct 2001
Squamous Cell Carcinoma of Head and Neck	EU	biolitec Pharma Ltd.	24 Oct 2001

Developing

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Advanced Head and Neck Carcinoma	Phase 2	US	biolitec Pharma Ltd.	01 Nov 2010
Squamous Cell Carcinoma of Head and Neck	Phase 2	US	biolitec Pharma Ltd.	01 Nov 2010
Carcinoma bile duct non-resectable	Phase 2	AT	biolitec Pharma Ltd.	01 Jan 2006
Carcinoma bile duct non-resectable	Phase 2	DE	biolitec Pharma Ltd.	01 Jan 2006

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT01016002 (not available, UEGW)	Phase 2	-	-	Temoporfin PDT	jlkpgmhwhq(gpqweoeosc) = phzjmujgwt vzteyrlvxf (frerqjtbil ) View more	Positive	01 Oct 2014
NCT01016002 (not available, UEGW)	Phase 2	-	-	Porfimer PDT	(btdcenjvya) = uxnotdqgqe ksleypdpgx (msbpkgciew, 11.7 - 19.1)	Positive	01 Oct 2014
NCT01016002 (Pubmed \| Photochem Photobiol Sci)	Phase 2	Bile Duct Neoplasms	-	Temoporfin PDT	(gmniqqalko) = knwqcgxjbs sdlxoxaynq (mxyieuvcuf, 4.4 - 32.0) View more	-	01 Jun 2013
TEM-HNC-001 (ASCO2008)	Not Applicable	Advanced Head and Neck Squamous Cell Carcinoma	39	Temoporfin-mediated photodynamic therapy	qwgqhvbwrz(sjrboawnng) = 21% of patients fmujhzapmc (ozxfnispxb ) View more	-	20 May 2008